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Purpose: Excessive or inappropriate non-steroidal anti-inflammatory drug (NSAID) use
during ultra-endurance events could cause potential risk to athletes’ health. Reports on
NSAID consumption in mountain bikers or ultra-mountain bikers are scarce. Therefore,
the aim of this study was to investigate the prevalence of NSAID consumption
immediately before, during and immediately after a mountain bike (MTB) race and to
compare NSAID consumption in two different MTB competitions.
Methods: This observational study took place at a three-stage MTB race (SMTB)
(n = 63) and at a 24-h MTB race (24MTB) (n = 68), both held in the Czechia in 2017.
NSAID consumption was evaluated via self-reported electronic questionnaires.
Results: Of all finishers (n = 131), fourteen (10%) consumed NSAID at least once during
the competition day (immediately before, during or immediately after the race). The
number of NSAID consumers was the same in both competitions. Nevertheless, only
three athletes (2%), all of them from the 24MTB, consumed NSAID during the race
and 5% of all mountain bikers reported consumption after the race. In contrast to the
SMTB, the intake reported by the 24MTB participants was quite homogeneous in terms
of the timing of NSAID consumption. The NSAID users were older (p = 0.043) than the
non-users. Ibuprofen was most commonly used by 79% of all consumers.
Conclusion: The prevalence of NSAID use was higher in the older participants and
seems to be lower in comparison with results from studies about runners, ultra-runners
and triathletes suggesting that it is determined by the discipline (i.e., cycling). On the
other hand, the timing of NSAID consumption was probably affected by the competition
character (e.g., MTBS or 24MTB). Future studies should focus on a larger sample size
of cyclists from various disciplines.
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly
used in sports medicine (Paoloni et al., 2009). A high rate of
non-prescribed use as well as a limited awareness about their
side effects has been reported previously (Gorski et al., 2011).
NSAID are one of the most commonly used medications for
the treatment of musculoskeletal pain and inflammation in all
classes of athletes (Ciocca, 2005). However, the use of these drugs
does not always induce a positive effect in athletes. Excessive or
inappropriate NSAID use during ultra-endurance events could
cause potential risk to the athletes’ health. For instance, it is
noteworthy that the use of NSAID did not appear to reduce the
development of muscle damage in a 160-km ultramarathon, and,
paradoxically, was associated with elevated biochemical markers
of inflammation (Nieman et al., 2006). Moreover, NSAID have
been indicated as a risk factor in the development of exercise-
associated hyponatremia (Davis et al., 2001; Wharam et al., 2006;
Page et al., 2007; Warden, 2010) and may subsequently enhance
the development of rhabdomyolysis (Bruso et al., 2010). Besides,
NSAID may probably affect renal functions by increasing the
effect of water retention by arginine vasopressin in kidneys (Baker
et al., 2005; Warden, 2010) and reducing glomerular filtration rate
(Murray and Brater, 1990).
Given the high level of NSAID consumption in ultra-
marathons, the renal system seems to be particularly prone to
injury at this type of competition (Wharam et al., 2006; Hoffman
and Fogard, 2011). NSAID use during an ultra-endurance race
can lead to an impaired muscle recovery from exercise as well
as to the inhibition of skeletal muscle adaptation to training
(Warden, 2009). NSAID have side-effects, such as asthma
exacerbation, gastrointestinal problems, hypertension and other
cardiovascular diseases (Paoloni et al., 2009). Nevertheless, the
results of the above mentioned and other related studies are often
conflicting and further investigation is necessary to determine the
potential risks of NSAID use in athletes (Hew-Butler et al., 2015).
From the overview above it is evident that the prevalence of
NSAID use in various endurance disciplines has been thoroughly
documented in the literature. However, to the best of our
knowledge, this topic has not been examined in mountain bike
(MTB) disciplines so far. Moreover, only a few studies reported
NSAID consumption at multiple timings during endurance
events (Joslin et al., 2013; Martínez et al., 2017). There has been an
increasing scientific interest for MTB as many mountain bikers
participate in races for enjoyment, health and fitness, event status,
team, social interaction, relaxation and dedication (Shafer and
Scott, 2013). In addition, ultra-endurance MTB, where mountain
bikers have to cover distances of more than 100 km and large
altitude changes, gets very popular, too (Gloor et al., 2013).
Therefore, the aim of the present study was to evaluate NSAID
use by mountain bikers. The 30–47% of long distance triathletes
(Wharam et al., 2006; Gorski et al., 2011), 35–75% of ultra-
marathon runners (Nieman et al., 2006; Hoffman and Fogard,
2011) and 46% of marathoners (Tillander et al., 2018) were found
to ingest NSAID during competition. Similar results (about 48%
of the athletes involved in the study) were observed in ultra-
endurance mountain running events with various race distances
ranging from marathon to ultra-distance of 112 km (Martínez
et al., 2017). We assumed therefore a similarity in race and
recovery NSAID use in mountain bikers compare to runners
and triathletes, because these type of endurance races require
relatively homogenous preparation and also recuperation and
a possibility of pain experience during the race. Unique data
representing NSAID consumption at three different time points –
immediately before, during and immediately after the race –
were used in this study. Furthermore, for the first time, NSAID
consumption was analyzed via data collected in two different
MTB competitions differing in their character and duration – a
three-stage race and a 24-h race.
MATERIALS AND METHODS
Data Collection
The protocol was in accordance with the Declaration of Helsinki
regarding research on human subjects and was approved by
the local institutional ethics committee at the Centre of Sports
Activities, Brno University of Technology, Brno, Czechia. All
competitors (over 18 years of age) were previously informed
about the study. Information about a forthcoming post-race
survey was included in pre-race e-mail correspondence with
entries from race directors of both races. An e-mail that invited
their participation in a on-line survey was sent the day after
the race. About 10 days later, an attempt was made to contact
those who had still not responded. The survey was closed 30 days
after the race. Written informed consent was obtained from
all research participants. A questionnaire based on a previous
study (Martínez et al., 2017) was verified and fine-tuned during
a pilot study, conducted in 2016 on fifteen 24-h mountain bikers
and ten multi-stage mountain bikers with a varying endurance
experience.
The questionnaire included questions covering the following
topics: (a) general information about the participants (e.g., sex,
age, self-reported weight, height and weekly training load);
(b) general information about NSAID consumption (e.g., with
the following options: habitual/daily use of NSAID, use on a
competition day, before competition, during competition, or
after competition, none); (c) timing of NSAID consumption
(e.g., with the following options: use before, during or after
competition, none); (d) the kind of NSAID used (e.g., with
the following options: ibuprofen, aspirin, naproxen, nimesulide,
diclofenac, dexketoprofen, salicylic, other, none) and dose in
mg; (e) reasons of NSAID consumption (e.g., with the following
options: pain prevention, pain relief, injury treatment, other)
and (f) prescription (e.g., medical prescription, own decision,
suggestion of teammates, other). BMI was calculated using body
mass and body height.
Participants
Sixty-two amateur multi-stage MTB racers (60 men and 2
women) and sixty-eight 24-h mountain bikers (65 men and
3 women), who finished the race, volunteered to take part in
the study (23% of the total 276 finishers and 19% of the total
349 finishers, respectively). Basic demographic and training data
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about all the mountain bikers including their race performance
is shown in Table 1. Pre-race characteristics of the multi-stage
MTB racers show that their age ranged from 31 to 48 years, body
mass index (BMI) ranged from 21 to 29 kg/m2 and their pre-
race training load was at 4–15 h per week. Pre-race characteristics
of the 24-h MTB racers show that their age ranged from 37 to
57 years, BMI from 23 to 29 kg/m2 and their training load at
4–10 h per week.
Multi-Stage MTB Race and 24-h MTB
Race
Two races were monitored: The ‘Kupkolo.cz MTB Trilogy’ multi-
stage MTB race and the ‘24-h MTB 2017’ MTB race. The
‘Kupkolo.cz MTB Trilogy’ multi-stage MTB race took place
from July 5 to July 8, 2017 in Teplice nad Metují, Czechia.
The 4-day race consisted of a prolog and three stages. The
prolog covered 8 km with 300 m difference in elevation,
stages 1 and 2 covered 70 km each and stage 3 was 80 km
long, with approximately 8,400 m of total elevation. The stage
routes consisted predominantly of trails, interrupted by only
a few road sections. During the race, the average temperature
reached 23 ± 4◦C and the relative humidity was 54 ± 1%.
In this competition, total finishing time (i.e., considering all
competitions days) was used as a characteristic representing the
competitors’ performance.
As regards the 24-h competition, the data was collected at the
8th edition of the ‘24-h MTB 2017’ MTB race in Jihlava, Czechia.
The participants started at 12:00 on May 19 and finished at 12:00
on May 20, 2017. The course comprised a 9.5 km single-track with
an elevation of 220 m. The average temperature was 17 ± 3◦C
and the relative humidity was 76 ± 5% during the race. In this
case, the overall distance (in km) covered within 24 h was used to
evaluate the performance.
Statistical Analysis
Statistical analysis was performed using Matlab R2014b (The
MathWorks, Inc., United States). Continuous data (basic
characteristics) was expressed as mean ± standard deviation,
whereas categorical data (questionnaire outputs) was shown
as frequency counts and percentages. All data was distributed
normally according to the Shapiro–Wilk test (p < 0.05).
A parametric t-test was then used to test the differences
in the continuous data among all finishers of the multi-
stage MTB race and the 24-h MTB race. Mann–Whitney
U-test was used to test the differences in the continuous
data between non-participants and participants of the study,
between NSAID consumers from the MTB multi-stage race
and the 24-h race and between all non-consumers and all
consumers (t-test is not suitable in this case due to the
low number of samples). The differences in categorical data
between the above data groups were assessed by Fisher’s
exact test. In all tests, p < 0.05 was considered statistically
significant.
RESULTS
General Information About Study
Participants
When comparing the two data sets (Table 1), the 24-h mountain
bikers were significantly older, with a higher body mass, a higher
BMI and a lower training load 3 months prior to the competition
than the multi-stage mountain bikers. Body height was the only
characteristic which showed no significant difference between
the data sets. The finishing time after the multi-stage MTB race
calculated from all study participants’ results ranged from 13 h
28 min to 37 h (with the mean time of 21 ± 6 h) corresponding
to 4th to 203rd place in the full list (regarding all 276 finishers).
Multi-stage mountain bikers who consumed NSAID completed
the race in 22 ± 4 h (ranging from 16 h to 25 h 20 min),
corresponding to the 27th–119th place in the full list. The mean
distance covered in the 24-h MTB race was 257 ± 56 km and
ranged from 158 to 369 km, which corresponds to the 40th–
123th place in the overall order (of all 349 finishers). Those who
consumed NSAID in the 24-h MTB race covered 222 ± 39 km
(ranging from 185 to 265 km), which corresponds to the 66th–
109th place in the overall order.
Basic demographic characteristics of study participants were
similar to those of non-participants (i.e., those racers, who did
not complete the questionnaire). As for multi-stage MTB race,
the group of non-participants involved 5% (n = 10) and 95%
(n = 204) of women and men, respectively. In participants of the
study, these values were 3% (n = 2) and 97% (n = 60), respectively
(see above). The non-participants’ age ranged from 18 to 59 with
mean value of 35± 7 years. No significant differences were found
in age between multi-stage mountain bakers who participated
and did not participate the study (p = 0.33). In 24-h MTB race,
women and men number in non-participants reached 4% (n = 11)
and 96% (n = 281), respectively. It completely corresponded with
TABLE 1 | Pre-race characteristics and race performance of mountain bikers.
Total (n = 130) MTB multi-stage race (n = 62) 24-h MTB (n = 68) p-value
Age (years) 37 ± 9 35 ± 8 39 ± 9 0.006
Body mass (kg) 79 ± 10 77 ± 9 82 ± 10 0.003
Height (cm) 181 ± 7 181 ± 6 182 ± 8 0.601
Body mass index (kg/m2) 24 ± 2 23 ± 2 25 ± 2 0.0005
Training load (hours/week) 9 ± 4 10 ± 5 8 ± 4 0.029
Performance – 21 ± 6 h 257 ± 56 km –
Expressed as mean ± standard deviation. MTB, mountain biking.
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TABLE 2 | Age, body mass index, and pre-race training load of mountain bikers who consumed NSAID.
Total (n = 14) MTB multi-stage race (n = 7) 24-h MTB (n = 7) p-value∗
Age (years) 43 ± 10 39 ± 8 43 ± 7 0.665
Body mass index (kg/m2) 25 ± 3 24 ± 3 26 ± 2 0.138
Training load (hours/week) 9 ± 4 11 ± 4 7 ± 2 0.06
∗Mann–Whitney U-test, p < 0.05.
the percentages obtained in participants (see above). The age
in non-participants ranged from 19 to 70 with mean value of
40± 10 years, which was not significantly different from the same
characteristic in the participants (p = 0.615).
General Information About NSAID Use
Age, BMI, and pre-race training load of mountain bikers who
consumed NSAID are shown in Table 2. The number of NSAID
consumers in the multi-stage MTB race and in the 24-h MTB
race was the same with 10% of all participants. We found no
significant difference between the two groups with respect to
their age, BMI or training load (p > 0.05) (Table 2). Pre-
race parameters of NSAID consumers and non-consumers are
shown in Table 3. NSAID users were older than non-users
(p = 0.043) and there was a non-significant difference in BMI,
but on the border of significance (p = 0.052) (Table 3). Age
was not associated with race performance (hours or kilometers)
and training load during the 3 months prior to the race
(p> 0.05) neither in all mountain bikers (n = 130), nor in NSAID
consumers (n = 14).
Information About Timing of NSAID
Consumption
Of all participants, 10% reported using NSAID at least once
on the competition day (i.e., immediately before, during or
immediately after the competition) (Table 4). There was no
statistical difference regarding the timing of consuming between
the multi-stage MTB race and the 24-h MTB race participants
(Tables 4, 5). Prior to the race, NSAID consumption was the same
in both groups. The 24-h MTB racers used NSAID throughout
the whole competition day and most of them reported using
NSAID during the race (Table 5). On the contrary, multi-stage
MTB racers mainly reported NSAID intake after the competition
without NSAID use during the race (Table 5). None of the
participants combined NSAID intake during the competition
with the intake before or after the competition.
Types and Doses of NSAID Intake
Of all the NSAID provided as options in the questionnaire, only
ibuprofen, diclofenac and nimesulide were taken by the study
participants. The 79% of them reported using only ibuprofen
(Table 6). Two consumers from the 24-h MTB race reported
using diclofenac and one reported using nimesulide. Diclofenac
was used before and after the competition, whereas nimesulide
was used during the competition (Table 6). Multi-stage mountain
bikers only used ibuprofen before and after the competition. The
average consumption of ibuprofen reached 400–800 mg among
the study participants (Table 7). Nevertheless, two out of seven
multi-stage mountain bikers took 1,600–2,000 mg of ibuprofen
(Figure 1), which resulted in a higher mean and standard
deviation of the analyzed value in this group in comparison
with the 24-h mountain bikers (Table 7). Despite this fact, no
significant difference was found in the ibuprofen consumption
between the competitions. Similar results were obtained when
taking into the account the duration of the race and expressed
the consumption per hour of the competition (Table 7). When
the two mountain bikers from the multi-stage MTB race with
abnormal consumption (see above) were not considered, the
average consumption was 27 ± 9 mg/h, which is similar to the
consumption in the 24-h MTB group.
Reasons for NSAID Use
The distribution of consumers regarding their reason for NSAID
use in both races is shown in Figure 1. Obviously, the main
reason for NSAID use in both competitions was pain relief,
reported by 57% of all NSAID consumers (n = 14). About 14%
of the consumers from both races used the drugs to prevent pain.
Besides above-mentioned options in the questionnaire, other
reasons, such as injury treatment, better relaxation and sleep after
the race, muscle inflammation reduction or treatment of cold
were reported by mountain bikers (Figures 1A,B). Only one 24-h
MTB participant followed medical prescription for NSAID use.
The other participants from both groups (93%) followed their
own decision. None of the racers reported using NSAID upon
recommendation by a team-mate.
DISCUSSION
This study is the first to describe the use of NSAID in the
context of a MTB race. The aim of this study was to evaluate
TABLE 3 | Pre-race characteristics of consumers and non-consumers of NSAID.
NSAID
non-consumers
(n = 116)
NSAID
consumers
(n = 14)
p-value∗
Age (years) 36 ± 9 43 ± 10 0.043∗
Body
mass (kg)
79 ± 10 80 ± 7 0.709
Height (cm) 182 ± 7 178 ± 8 0.093
Body mass
index
(kg/m2)
24 ± 2 25 ± 3 0.052
Training
load
(hours/week)
9 ± 4 9 ± 4 0.916
∗Mann–Whitney U-test, p < 0.05.
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TABLE 4 | Pattern of NSAID consumption.
Total (n = 130) MTB multi-stage race (n = 62) 24-h MTB (n = 68) p-value
Habitually∗ 6 (5%) 2 (3%) 4 (6%) 0.682
Competition day∗∗ 13 (10%) 6 (10%) 7 (10%) 1.000
Before competition 4 (3%) 2 (3%) 2 (3%) 1.000
During competition 3 (2%) 0 3 (4%) 0.246
After competition 7 (5%) 5 (8%) 2 (3%) 0.257
Expressed as a number of participants in the corresponding category and as a percentage of the total number of participants in the corresponding category. MTB,
mountain biking. ∗ indicates daily use of NSAIDs, ∗∗ indicates consumption either immediately before, or during or immediately after the race.
TABLE 5 | Distribution of NSAID use in NSAID consumers.
Total (n = 14) MTB multi-stage race (n = 7) 24-h MTB (n = 7) p-value
Before competition 4 (29%) 2 (29%) 2 (29%) 1.000
During competition 3 (21%) 0 3 (42%) 0.192
After competition 7 (50%) 5 (71%) 2 (29%) 0.286
Expressed as a number of participants in the corresponding category and as a percentage of the total number of participants in the corresponding category. MTB,
mountain biking.
TABLE 6 | Distribution of ibuprofen and other NSAIDs.
Total (n = 14) MTB multi-stage race (n = 7) 24-h MTB (n = 7)
Before competition Ibuprofen 3 (75%) 2 (100%) 1 (50%)
Other 1 (25%) 0 1 (50%)
During competition Ibuprofen 2 (67%) 0 2 (67%)
Other 1 (33%) 0 1 (33%)
After competition Ibuprofen 6 (86%) 5 (100%) 1 (50%)
Other 1 (14%) 0 1 (50%)
Expressed as a number of participants in the corresponding category and as a percentage of the total number of participants in the corresponding category. MTB,
mountain biking.
TABLE 7 | Ibuprofen consumption during the competition day.
Total (n = 11) MTB multi-stage race (n = 7) 24-h MTB (n = 4) p-value
Mg 840 ± 548 1000 ± 657 600 ± 231 0.283
mg/hour of competition 39 ± 29 48 ± 35 25 ± 10 0.476
Expressed as mean ± standard deviation. MTB, mountain biking.
and compare the prevalence of NSAID consumption immediately
before, during and immediately after a MTB multi-stage race and
a 24-h MTB race.
General Information About NSAID Use
The main finding was the predominance of mountain bikers who
did not use any NSAID before, during and after the race. Of all
the finishers, only 10% consumed NSAID at least once on the
competition day (i.e., immediately before, during or immediately
after the race). NSAID use during marathon (Joslin et al., 2013;
Tillander et al., 2018) and ultra-marathon running (Nieman et al.,
2005; McAnulty et al., 2007; Hoffman and Fogard, 2011; Joslin
et al., 2013; Martínez et al., 2017) has been previously reported.
In a study conducted in 161-km ultra-runners (Hoffman and
Fogard, 2011), where NSAID intake was high (about 56% of all
study participants), overall drug use was even higher in official
finishers than in non-finishers. When we compare running and
ultra-running results with ultra-endurance events involving less
eccentric exercise, the prevalence of NSAID use was 30% in
Ironman triathlon (Wharam et al., 2006) and during a long-
distance triathlon the consumption of NSAID reached 47%
(Gorski et al., 2011). With regard to the fact that we found no
study about NSAID consumption among mountain bikers, the
overall NSAID consumption in the present study was relatively
low in comparison with runners and triathletes in other studies.
The reason could be the lack of typical runners’ medical issues
during the race among mountain bikers. For example, blisters as
the most commonly encountered medical problem representing
17–40% of injuries at continuous ultra-marathons and 33–74%
of injuries during multi stage ultra-marathons; further subungual
hematomas, gastrointestinal distress and musculoskeletal injuries
representing 1–24% of injuries during continuous and 18–22%
during multi stage ultra-marathon running races (Hoffman and
Fogard, 2011; Krabak et al., 2011).
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FIGURE 1 | Reasons for NSAID consumption in the MTB multi-stage race (A) and in the 24-h MTB race (B). Expressed as a percentage (%) of the total number of
consumers in the corresponding category.
The next important finding was that NSAID users were found
to be older than non-users. It appears that older athletes had a
specific motivation, such as a strong need to finish the race despite
pain; however, we did not investigate these psychological factors.
Nevertheless, we have to take into account the fact that there may
be other factors that we have not studied in this study and which
could affect NSAID intake. We can suggest that NSAID intake
seems to be lower in comparison with results from studies in
runners, ultra-runners and triathletes in the present study.
Information About Timing of NSAID
Consumption
A further important finding was that only 2% from all NSAID
consumers used NSAIDs during the race and the 3% used NSAID
prior competition. With regard to the timing of NSAIDs, 26% of
marathon, half-marathon and marathon relay runners reported
NSAID use during competition (Joslin et al., 2013). Even 70% of
ultra-marathon runners from the same study were more likely to
use NSAID during the 148-mile multi stage race. Twenty percent
of 60-km mountain runners used non-selective and 15% selective
NSAID before and during the race (Page et al., 2007). The 72%
runners consumed NSAID during a 160-km ultra-marathon,
(Nieman et al., 2005). During a long-distance triathlon the 47%
consumption of NSAID was the day before, immediately before
and during the race (Gorski et al., 2011). In a 112-km running
race (Martínez et al., 2017), NSAID consumers reported the
lowest intake before and the highest intake during the race, while
marathoners in the same study reported similar consumption
levels before and during the race (Martínez et al., 2017). When
we compare the above-mentioned results, we have to take into
account the fact that some studies did not exactly clarify if they
differentiated between NSAID consumption before and during
the race. Nevertheless, a high NSAID consumption during or
immediately before a race may put participants at an increased
risk of adverse events (Davis et al., 2001; Baker et al., 2005;
Wharam et al., 2006; Page et al., 2007; Bruso et al., 2010; Hoffman
and Fogard, 2011). With regard to the low NSAID consumption;
moreover, consisting from 50% of pre- or during race NSAID
intake, the risk of potential medical complications in mountain
biker was probably low.
The 5% of mountain bikers reported NSAID use after the
race. The marathon runners and ultra-runners both used NSAIDs
particularly during recovery and NSAID use was greater in ultra-
marathon runners only during the race (Joslin et al., 2013). We
confirmed the similarity in recovery NSAID use in mountain
bikers compare to runners. Mountain bikers from both races
consumed NSAID after the race without significant difference
between continuous race – 24-h MTB race and stage race – multi
stage MTB race.
Multi-Stage MTB Versus 24-h MTB
NSAID Consumption
A further important finding was the fact that we found no
statistical significant difference in NSAID consumption between
the group of 24-h mountain bikers and multi-stage mountain
bikers. Although the 24-h mountain bikers were significantly
older, with a higher body mass and a higher BMI and a lower
training load 3 months prior to the competition we found no
association between these parameters and the use of NSAID in
comparison to NSAID users in the multi-stage race. A potential
explanation could be the different numbers in athletes in the
two groups. The only difference between the groups was that
NSAID consumption was homogeneous throughout the whole
competition day in the 24-h MTB racers, whereas the multi-
stage MTB racers predominantly used NSAID after the race.
These differences could be related to the type of the race, because
multi-stage mountain bikers had to complete three difficult stages
and they want to regenerate and be ready for the next day. On
the contrary, continuous character of the race and its duration
probably had an influence on the consumption of NSAID during
the race only in the 24-h mountain bikers.
Types of NSAID Intake and Reasons for
NSAID Consumption
Three different kinds of NSAID were consumed in the present
study, with the predominance of ibuprofen. It corresponds with
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the results of Martínez et al. (2017) and Nieman et al. (2005),
where it was shown that ibuprofen was taken by 87% and
86% of runners used NSAID, respectively. A large number of
athletes take NSAID for their analgesic effects (Nieman et al.,
2006; Hoffman and Fogard, 2011). Runners reported NSAID
use during competition to help with pain and inflammation
(Joslin et al., 2013). Pain relief and the prevention of pain were
the most often cited reasons for NSAID consumption in the
present study in agreement with previous studies (Gorski et al.,
2011; Didier et al., 2017; Martínez et al., 2017). However, no
beneficial effects of ibuprofen on decreasing muscle soreness
caused by muscle injury were reported (Peterson et al., 2003;
Nieman et al., 2005). Moreover, consideration should be taken
before ingesting NSAID (ibuprofen) during endurance running,
because increased rate of acute kidney injury was reported
in those ultra-marathoners who took ibuprofen in a study
of Lipman et al. (2017). Renal stress, fluid imbalance and
potential acute kidney injury are apparent when cycling in
the heat is longer than 5 h and even moderate ibuprofen
ingestion had no influence on increased renal biomarkers in road
cyclists post-race (McDermott et al., 2018). Although runners
prevent muscle soreness caused by eccentric muscle contraction
(especially during hill descents) by NSAID consumption, the
mountain bikers in our study with predominantly concentric
contraction also used NSAID. The main reason for NSAID
use in the 24 h mountain bikers was pain relief during and
after competition caused probably by the length and continuous
load of the 24-h MTB race. The most of multi stage mountain
bikers also reported pain relief, followed by pain prevention,
injury, cold and muscle inflammation treatment as reasons for
prior or after the race NSAID consumption caused probably
by demanding repeated stages load. We can assume that
older NSAID users who reported more frequently NSAID
consumption had probably more medical issues or proven
strategy for coping with injury. Tillander et al. (2018) found
that runners who reported NSAID use in the past year reported
significantly fewer injuries. Anyway, the NSAID consumption
was relatively low in the present study. The reason for relatively
low NSAID use could be the fact that we examined mountain
bikers with recreational approach to sport and they were probably
motivated also by personal achievement and general health and
were aware of the danger related to drug consumption during a
race.
Limitations, Strength, and Practical
Applications
The main limitation of the study is the presence of the
biases (such as selection bias, response bias, etc.), which are
well known source of the incorrectness in a wide range of
study designs, including those based on the questionnaires
(Pannucci and Wilkins, 2010). Since, we were conscious of
that, particular effort was made in different phases of the
study planning and conduction to avoid or at least reduce
the biases. Particularly, potential bias sources were considered
when designing questionnaire and planning the study. The
questionnaire included quite small number of questions, which
were phrased well (i.e., with no “sensitive” formulations)
and mostly required answering by simple selection from the
predefined list to avoid the participant fatigue as well as
ambiguous answers. The questionnaire was available in two
languages (Czech and English) to reduce number of people, who
did not participate in the study due to language barrier, and,
consequently, to make the study more representative by including
as many people as possible. The racers were informed about a
postrace survey via e-mail 1 month before the competition and
were additionally invited to the participation 1 day after the
race. In both correspondences, no details about the study were
included to avoid the affecting of the participants. The online
questionnaire was available for 30 days after the competition.
Thus, the questions could generally be answered anonymously,
independently of other participants, coaches, etc. This time delay
might also eliminate the effect of participants’ tiredness present
immediately after the race.
During data collection, unfortunately, selection bias cannot
be avoided, when people volunteer for a study (so called “self-
selection”). There are many methods to reduce selection bias,
but the most of them required data from the general population
or/and non-participants besides data from the tested group
(Keeble et al., 2015). These assumptions are not satisfied in
present study due to uniqueness of dataset and the character
of the study, where most data are only available for study
participants. Further, the participant number could be higher.
However, it seems to be similar to that of other studies based
on self-reported data focusing on NSAID use (Wharam et al.,
2006; Page et al., 2007; Joslin et al., 2013; Martínez et al., 2017).
Since the basic demographic characteristics (sex and age) of study
participants and the wider population (i.e., the racers, who did
not participate) are similar, reported results may be applied –
though with a caution – on the general population.
Finally, self-report – a source of response (or reporting) bias –
has been the primary method used to assess NSAID use during
ultra-endurance events in the field studies. Thus, data should
be interpreted with a caution. Nevertheless, confidentiality of
data and their representation in a “judgment free” manner,
generally “neutral” character of NSAIDs (they are not forbidden
or illegal and many people do not know about negative side-
effects or positive effects of NSAIDs) eliminated or at least
reduced so called “social desirability” effect, which often leads to
the reporting bias in self-reporting data.
The findings of the present study were based on data collected
through a web electronic survey using similar questions as those
of Martínez et al. (2017). Thus, caution would be needed to
compare these findings with studies on NSAID prevalence using
different methodology.
Despite above aspects, this is the first study of NSAID in MTB
athletes, which considering the increasing popularity of this sport
would have practical applications for health practitioners and
strength and conditioning coaches working with MTB athletes.
Medical staff at endurance events need to be aware of potential
complications related to eventually excessive use of NSAID in
cyclists or athletes in other sport disciplines. Although NSAID
use seems to be lower than in runners, ultra-runners and
triathletes; a certain percentage of NSAID users has nevertheless
occurred also among mountain bikers. Future studies should
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focus on larger sample size of mountain bikers and also cyclists
from different cycling disciplines.
CONCLUSION
The prevalence of NSAID consumption was higher in the older
participants and seems to be lower in comparison with results
from studies in runners, ultra-runners and triathletes suggesting
that it is determined by the discipline (cycling). On the other
hand, whether NSAID consumption occurs immediately before,
during or immediately after the race is probably determined
by the competition character (multi-stage competition or 24-h
race).
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